Peng Zhouying, Wang Yumin, Fan Ruohao, Gao Kelei, Xie Shumin, Wang Fengjun, Zhang Junyi, Zhang Hua, He Yuxiang, Xie Zhihai, Jiang Weihong
Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Otolaryngology Major Disease Research Key Laboratory of Hunan Province, Changsha 410008, China.
Cancers (Basel). 2022 Aug 25;14(17):4111. doi: 10.3390/cancers14174111.
Recurrent nasopharyngeal carcinoma (NPC), which occurs in 10-20% of patients with primary NPC after the initial treatment modality of intensity-modulated radiation therapy (IMRT), is one of the major causes of death among NPC patients. Patients with recurrent disease without distant metastases still have a chance to be saved, but re-treatment often carries more serious toxicities or higher risks. For this group of patients, both otolaryngologists and oncologists are committed to developing more appropriate treatment regimens that can prolong patient survival and improve survival therapy. Currently, there are no international guidelines for the treatment of patients with recurrent NPC. In this article, we summarize past publications on clinical research and mechanistic studies related to recurrent NPC, combined with the experience and lessons learned by our institutional multidisciplinary team in the treatment of recurrent NPC. We propose an objective protocol for the treatment of recurrent NPC.
复发性鼻咽癌（NPC）发生于接受调强放射治疗（IMRT）初始治疗的原发性NPC患者中的10%-20%，是NPC患者主要死亡原因之一。无远处转移的复发性疾病患者仍有挽救机会，但再次治疗通常会带来更严重的毒性或更高风险。对于这组患者，耳鼻喉科医生和肿瘤学家都致力于制定更合适的治疗方案，以延长患者生存期并改善生存治疗。目前，尚无复发性NPC患者治疗的国际指南。在本文中，我们总结了过去有关复发性NPC的临床研究和机制研究的出版物，并结合我们机构多学科团队在复发性NPC治疗中的经验教训。我们提出了一种复发性NPC的客观治疗方案。
